Know Cancer

forgot password

Treatment of Cystic Hygroma (Lymphangiomas) in Children- Picibanil(OK432) Sclerotherapy-Multicenter Trial

Phase 2/Phase 3
6 Months
18 Years
Open (Enrolling)
Lymphatic Malformations

Thank you

Trial Information

Treatment of Cystic Hygroma (Lymphangiomas) in Children- Picibanil(OK432) Sclerotherapy-Multicenter Trial

PROTOCOL OUTLINE: This is a multicenter study. Patients are stratified according to prior
treatment (no prior treatment vs prior surgical treatment) and geographic area.

Patients who meet all study criteria are put in the "Immediate Treatment Group." Patients
receive an intralesional injection of picibanil (OK432) with the aid of ultrasonography or
transillumination for localization of cysts. Treatment repeats every 6-8 weeks for a total
of up to 4 injections.

After completion of treatment, patients are followed at 6 months, 1 year, and 2 years.

Inclusion Criteria


--Disease Characteristics--

- Diagnosis of macrocystic lymphangioma of the head and/or neck Cystic spaces at least
2.0 mL confirmed by radiographic imaging (MRI or CT) Mixed lymphangiomas (macrocystic
and microcystic disease) allowed if macrocystic component comprises at least 50% of
the total disease burden

- No mixed hemangioma-lymphangioma lesions

- At least 6 months since prior surgery for lymphangioma

--Patient Characteristics--

- Hematopoietic: No clinically significant hematologic disease No hemodynamic

- Hepatic: No clinically significant hepatic disorder

- Renal: No clinically significant renal disease No personal or family history of
post-streptococcal glomerulonephritis

- Cardiovascular: No personal or family history of rheumatic heart disease

- Pulmonary: No respiratory failure


- Not pregnant or nursing

- Negative pregnancy test

- No history of allergy to penicillin

- No concurrent temperature of 100.5 degrees or greater

- No active upper respiratory infection

- No personal or family history of obsessive-compulsive or tic disorders

- No personal or family history of PANDA (pediatric autoimmune neuro- psychiatric
disorder associated with streptococcal infections)

- No history of hypersensitivity to iodine, Omnipaque, or gadolinium (if fluoroscopy is
considered necessary)

- No history of poor health (including congenital disorders, chronic diseases, or
immunologic dysfunction)

Type of Study:


Study Design:

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

to establish whether OK432 sclerotherapy is an effective form of treatment for lymphatic malformations versus the traditional form of treatment, which is surgical excision.

Outcome Time Frame:


Safety Issue:


Principal Investigator

Richard J Smith

Investigator Role:

Study Chair

Investigator Affiliation:

University of Iowa


United States: Federal Government

Study ID:




Start Date:

April 2000

Completion Date:

Related Keywords:

  • Lymphatic Malformations
  • cystic hygroma
  • lymphangiomas
  • lymphatic malformations
  • Congenital Abnormalities
  • Lymphangioma
  • Lymphangioma, Cystic
  • Lymphatic Abnormalities



Childrens National Medical Center Washington, District of Columbia  
University of Iowa Hospitals and Clinics Iowa City, Iowa  52242
Children's Hospital of Denver Denver, Colorado  80218
All Children's Hospital St. Petersburg, Florida  33701
Children's Hospitals and Clinics - Minneapolis Minneapolis, Minnesota  55404
University of Wisconsin Hospital and Clinics Madison, Wisconsin  53792-0001
Vanderbilt University Nashville, Tennessee  37232-6305
Children's Associated Medical Group San Diego, California  92123
SUNY Upstate Medical University Syracuse, New York  13210
Oregon Health Sciences University Portland, Oregon  
Texas Pediatric Otolaryngology Center Houston, Texas  77030
Children's Hospital of the Kings Daughter Norfolk, Virginia  23507
Children's Hospital of Wisconsin Milwaukee, Wisconsin  53201